Nuvectis Pharma, Inc. (NVCT) 10-Year Financial Performance & Capital Metrics

NVCT • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutNuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.Show more

Revenue $0
EBITDA -$19M +17.0%
Net Income -$19M +14.6%
EPS (Diluted) -1.11 +22.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -173.41% -2.9%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 10.0% in last year
✗Expensive at 15.0x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-30.98%

EPS CAGR

10Y-

5Y-

3Y-

TTM-14.99%

ROCE

10Y Avg-199.95%

5Y Avg-199.95%

3Y Avg-187.63%

Latest-181.14%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-
Gross Profit+	0	0	0	0	0
Gross Margin %	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-
Operating Expenses+	10K	12.89M	19.23M	22.9M	19.85M
OpEx % of Revenue	-	-	-	-	-
Selling, General & Admin	10K	3.35M	6.01M	7.52M	6.93M
SG&A % of Revenue	-	-	-	-	-
Research & Development	0	9.54M	13.23M	15.38M	12.92M
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0
Operating Income+	-10K	-12.89M	-19.23M	-22.9M	-19.85M
Operating Margin %	-	-	-	-	-
Operating Income Growth %	-	-1288.4%	-0.49%	-0.19%	0.13%
EBITDA+	-10K	-12.89M	-19.23M	-22.9M	-19M
EBITDA Margin %	-	-	-	-	-
EBITDA Growth %	-	-1288.4%	-0.49%	-0.19%	0.17%
D&A (Non-Cash Add-back)	0	0	0	0	0
EBIT	-10K	-12.89M	-19.23M	-22.9M	-19M
Net Interest Income+	0	4K	149K	637K	847K
Interest Income	0	4K	149K	637K	847K
Interest Expense	0	0	0	0	0
Other Income/Expense	0	4K	149K	637K	847K
Pretax Income+	-10K	-12.89M	-19.09M	-22.26M	-19M
Pretax Margin %	-	-	-	-	-
Income Tax+	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-10K	-12.89M	-19.09M	-22.26M	-19M
Net Margin %	-	-	-	-	-
Net Income Growth %	-	-1288%	-0.48%	-0.17%	0.15%
Net Income (Continuing)	-10K	-12.89M	-19.09M	-22.26M	-19M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.00	-1.09	-1.51	-1.43	-1.11
EPS Growth %	-	-	-0.39%	0.05%	0.22%
EPS (Basic)	-0.00	-1.09	-1.51	-1.43	-1.11
Diluted Shares Outstanding	12.72M	12.72M	12.66M	15.56M	17.11M
Basic Shares Outstanding	12.72M	12.72M	12.66M	15.56M	17.11M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	0	5.83M	20.41M	19.18M	18.61M
Cash & Short-Term Investments	0	5.74M	19.99M	19.13M	18.53M
Cash Only	0	5.74M	19.99M	19.13M	18.53M
Short-Term Investments	0	0	0	0	0
Accounts Receivable	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	0	91K	412K	59K	74K
Total Non-Current Assets+	0	824K	0	0	0
Property, Plant & Equipment	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	0	824K	0	0	0
Total Assets+	0	6.66M	20.41M	19.18M	18.61M
Asset Turnover	-	-	-	-	-
Asset Growth %	-	-	2.07%	-0.06%	-0.03%
Total Current Liabilities+	10K	2.42M	6.19M	6.98M	8.89M
Accounts Payable	10K	1.06M	2.91M	2.77M	2.5M
Days Payables Outstanding	-	-	-	-	-
Short-Term Debt	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	0	142K	2.38M	3.8M	5.56M
Current Ratio	-	2.41x	3.30x	2.75x	2.09x
Quick Ratio	-	2.41x	3.30x	2.75x	2.09x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	0	15.25M	0	0	0
Long-Term Debt	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	0	15.25M	0	0	0
Total Liabilities	10K	17.66M	6.19M	6.98M	8.89M
Total Debt+	0	0	0	0	0
Net Debt	0	-5.74M	-19.99M	-19.13M	-18.53M
Debt / Equity	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-	-	-	-	-
Total Equity+	-10K	-11.01M	14.22M	12.2M	9.71M
Equity Growth %	-	-1099.8%	2.29%	-0.14%	-0.2%
Book Value per Share	-0.00	-0.87	1.12	0.78	0.57
Total Shareholders' Equity	-10K	-11.01M	14.22M	12.2M	9.71M
Common Stock	0	0	0	0	0
Retained Earnings	-10K	-12.9M	-31.98M	-54.24M	-73.25M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	0	0	0	0
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	0	-9.5M	-13.56M	-15.95M	-12.25M
Operating CF Margin %	-	-	-	-	-
Operating CF Growth %	-	-	-0.43%	-0.18%	0.23%
Net Income	-10K	-12.89M	-19.09M	-22.26M	-19M
Depreciation & Amortization	0	0	0	0	0
Stock-Based Compensation	0	1.89M	1.71M	4.71M	4.86M
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	0	0	0	-139K	0
Working Capital Changes	10K	1.49M	3.82M	1.74M	1.9M
Change in Receivables	0	0	0	0	0
Change in Inventory	0	0	0	0	0
Change in Payables	0	0	1.85M	-139K	-273K
Cash from Investing+	0	0	0	0	0
Capital Expenditures	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	0	0
Cash from Financing+	0	15.25M	27.81M	15.09M	11.65M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	0	0	-4.07M	9.8M	-382K
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	0	-9.5M	-13.56M	-15.95M	-12.25M
FCF Margin %	-	-	-	-	-
FCF Growth %	-	-	-0.43%	-0.18%	0.23%
FCF per Share	-	-0.75	-1.07	-1.03	-0.72
FCF Conversion (FCF/Net Income)	-	0.74x	0.71x	0.72x	0.64x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-1188.73%	-168.51%	-173.41%
FCF Conversion	-	0.74x	0.71x	0.72x	0.64x

Frequently Asked Questions

Growth & Financials

Nuvectis Pharma, Inc. (NVCT) grew revenue by 0.0% over the past year. Growth has been modest.

Nuvectis Pharma, Inc. (NVCT) reported a net loss of $25.4M for fiscal year 2024.

Dividend & Returns

Nuvectis Pharma, Inc. (NVCT) has a return on equity (ROE) of -173.4%. Negative ROE indicates the company is unprofitable.

Nuvectis Pharma, Inc. (NVCT) had negative free cash flow of $14.5M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener